Carrie Mendeville
Head of Investor Relations
Replay available
Guardant Health (NASDAQ:GH) Q2 2020 earnings call, held 2020-08-06. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/guardant-health-inc-gh-q2-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, thank you for standing by and welcome to the Guardian Health Q2 2020 earnings conference call. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question and answer session. To ask a question via the telephone line, please press star and the number 1 on your telephone keypad. I would like to now hand the call over to your speaker today, Ms. Carrie Mendeville, Investor Relations. Thank you. Please go ahead, ma'am.
0:30 Thank you. Earlier today, Garden Health released financial results for the quarter ended June 30th, 2020. If you've not received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors at gardenhealth.com. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties, that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward Looking Statements in the press release regarding the issue today. For a more complete list and description, please see the Risk Factors section of the company's annual report on Form 10-K for the year ended December 31st, 2019 and in its other filings with the Securities and Exchange Commission.
1:25 Except as required by law, Thanks, Keri. Good afternoon and thank you for joining our second quarter 2020 earnings call.
1:55 Joining me today is Amir Ali Talasaz, our president and co-founder, and Dara Khurshid, our chief financial officer. To start, I hope everyone is in the best of health and in good spirits in the face of the pandemic. As expected, the impact of COVID-19 created headwinds for the oncology space during the second quarter, and not surprisingly, various aspects of our business were affected to varying degrees, which I will review in a bit. That said, in the face of these ongoing challenges, The GARDEN team has continued to make substantial progress across our business, presenting new data for our Lunar 2 assay, announcing two new companion diagnostic partnerships, and launching our GARDEN-informed platform. Indeed, these past few months have made me more confident than ever in the promise of our platform and the significant opportunity ahead to transform patient care despite the challenges posed by the pandemic today.
2:52 I am extremely proud of the Darden team for the fire and dedication they have shown in this new environment. The fuel to the fire, so to speak, is our commitment to serve patients. And consistent with these values, I will start off our call with a patient story. Recently, a 60-year-old man presented with a brain mass, an initial workup at endometriosis. Unfortunately, his oncologist, who practices in the community setting, I've noticed that patients are coming in at more advanced stages due to delays in addressing symptoms as a result of a pandemic. The brain mask was the most urgent matter for this patient and brain surgery was performed. The provider was suspicious of lung cancer given the histology of the brain biopsy and the presence of lung nodules, but a lung biopsy following the brain procedure was deemed too risky.
3:45 His oncologist, meanwhile, tissues from his brain biopsy was sent out for genomic testing They were still awaiting results. The provider decided to try liquid biopsy and sent the GARDEN360 as the GARDEN360 user. GARDEN360 quickly identified a methexon 14 skipping alteration. Based on this result, the oncologist was able to select capimatinib for his first-line treatment. Not only does this story demonstrate the importance of the precision oncology paradigm, but it highlights how our liquid biases platform is uniquely qualified to address the needs of patients during this challenging time. Turning to our business, we ended the second quarter with revenue of 66.3 million, growing 23% over the second quarter of 2019.
4:36 Clinical volumes for GARDEN360 grew 15% to 13,694 clinical tests in part of the second quarter of 2019. On our last earnings call, I shared that our U.S. clinical volumes were down about 30% exiting the first quarter compared to the average level of clinical samples over the first quarter. In May, we had begun to see a slight uptick in sample volume from the lowest points in early April. We continue to see improvement in clinical volumes throughout May and into June and are pleased to report that we exited the quarter with volumes similar to the levels we saw in mid-March from COVID-19. Through this difficult time, our team was not only able to maintain uninterrupted operations, but was also able to consistently maintain our industry-leading turnaround time for Garden 360 of seven days or less.
5:33 Diving deeper into clinical volumes, growth recovered more quickly in community hospitals compared to the academic setting. Additionally, we saw a rapid shift towards telemedicine. Before the pandemic, we used telemedicine with just a few percent of visits performed virtually. Over the past few months, this trend has reversed itself to protect advanced cancer patients, an extremely high-risk population, from exposure to COVID-19. As a result, there have been fewer physical visits to oncology offices and fewer new diagnoses, factors that benefit the increased use of liquid biopsy testing, Thank you for joining us. This is counterbalanced by 29% year-over-year growth in development services revenue of $15.3 million. On the whole, we remain pleased with our biopharmaceutical business. AmirAli will give further detail in a few minutes.
7:03 We remain unwavering in our commitment to serving patients in advanced cancer settings and have continued to shift the market to a blood-birth paradigm for genotyping. At the end of 2018, we outlined three key catalysts that would be critical to shifting the market to a blood-first paradigm. First, demonstrating concordance between liquid biopsy and tissue testing. Second, pan-cancer Medicare coverage. And finally, FDA approval of GAR-360 with a pan-cancer tumor profiling label. In the first quarter, we began to see benefits from pan-cancer Medicare payments outside of non-small cell lung cancer. and we are looking forward to achieving the third for all solid tumor types.
7:49 We believe FDA approval will help to accelerate wider adoption of guideline-recommended genomic profiling, increasing the number of advanced cancer patients who receive potentially life-changing treatments. Specifically, we expect FDA approval to strengthen reimbursement by advancing conversations with private payers and further improving existing Medicare coverage, Extend momentum for our companion diagnostics business through increased opportunities to work with biopharma in the clinical settings. And over the medium to long term, advance the use of GARDEN360 with physicians who have been slow to adopt PGP. Looking ahead, we continue to believe that the unique opportunity we have here at GARDEN will allow us to serve patients with the disease.
8:35 During the quarter, we completed a follow-on offering, raising approximately We intend to use these funds to accelerate development in our lunar program and pursue the large market opportunities in front of us. I am incredibly proud of the outstanding efforts across our organization, and the last few months only reaffirm my belief that we will come out of this period even stronger as a company. With that, I will now turn the call over to Amir Ali for more detail on our biopharma business and our lunar program.
9:18 Thanks, Helmy. I hope all of you and your families are staying safe and healthy. Starting first, our biopharma business. As Helmy mentioned, we have a strong quarter of our CDX development services offset by your sample testing volumes. Starting with biopharma volumes. We have always noticed the likelihood of essence flows in our biopharma business. Back in February, on our 2019 year-end earning call, we anticipated that biopharma volumes would be lighter in the first half of the year. In addition to these anticipated fluctuations, COVID-19 has clearly impacted the sample testing and prospective studies, and also the time achievement of biobank samples from retrospective studies.
10:15 and Sirico through Biopharma sample testing audience. However, through conversations with our Biopharma partners, we continue to see robust future demand for sample processing, especially using Garden Omni. Conversely, we experience strong growth in our companion diagnostic business, which speaks to the progress we are making in our CDX product development activities, from our biopharma partners. We recently announced two new CDX partnerships. In early July, with Janssen for Aguivantamab, an investigational EGFR met by specific antibody being studied in the treatment of non-small cell lung cancer patients with EGFR exon 20 insertions, which comprise We are encouraged that our partners are recognizing the value of comprehensive testing to find these patients and to support the broad commercial penetration to accelerate uptake of these type of target therapies from the first day of approval.
11:35 Last week, we announced the CBA's collaboration with Radius Health for LSS-TRANS, Our first companion diagnostic program in breast cancer. Given the high prevalence of bone metastasis in advanced breast cancer disease, our GARDEN360 liquid biopsy can help overcome the challenges of bone biopsies by identifying significantly more actionable biomarkers, including ESR1 mutations, which are being studied in the RADIUS MRL trial. We are extremely pleased by the progress of our companion diagnostic business today and are encouraged by the healthy pipeline of other CVX discussions underway.
12:22 Our companion diagnostic program supports a critical expansion of target therapies, which we believe to be one of the most important drivers of Gordon 360 clinical adoption. 2020 has seen more new target therapies approved by FDA than prior years, and we are already seeing the positive effects in clinical volumes for indications with recent drug approvals, for example, in prostate cancer. We also remain deeply committed to continue generating robust data to further improve cancer diagnosis and treatment. We launched a real-world clinical genomic platform, Garden Informed, to help accelerate research and development of the next generation of cancer therapeutics.
13:14 Each Garden 360 test provides critical genomic information on various tumor profiles, and we have now collected this genomic information from more than 100,000 patients to date. GARDEN-INFORM combines this robust genomic data with de-identified clinical information for each patient. This clinical genomic dataset offers our biopharma partners real-world insight into how patients are treated based on their mutation profiles and the pattern of drug resistance and tumor evolution. The most notable applications for GARDEN-INFORM include target drug development and label expansion, Clinical Trial Optimization by incorporating real-world clinical genomic data into trial design and control arm development, as well as post-marketing studies.
14:11 Now, turning to our loaner program. We are continuing our research on clinical development activities at relatively full capacity. We have expanded our trial site in Eclipse to over 130 sites. Patient enrollment began to reactivate in late June, following lows throughout April. In fact, June was a record month of enrollment, and we have continued to see growth subsequently quartered out. Overall, we are very pleased with our progress, particularly during these difficult past few months, and we continue to believe we will complete enrollment within the The 24-month time frame announced last November.
15:02 Absolute Equips. We are also developing robust data in support of our Lunar 2 assay. At AACR, we share data from a new patient cohort that demonstrated improved performance of Lunar 2 assay to detect early stage colorectal cancer in average risk adults. Our assay achieved 90% sensitivity We recently filed for an emergency use authorization of our NGS assay and are currently using GivingHouse for save-life testing of Guardant employees.
16:01 As an essential business, weekly COVID-19 screenings have been critical to both keeping our employees safe and maintaining business continuity. We continue to believe that similar screening programs will be an important component of the sustained reopening of the economy and educational systems across the U.S. With that, I will now turn the call over to Derek Bertacci for more information and details about our financials. Derek?
16:33 Thanks, Amir Ali. Revenue for the second quarter of 2020 totaled $66.3 million, up 23% from $54 million in the prior year quarter, but down $1.2 million, or 2% from the first quarter of 2020. The increase from Q2 2019 was driven by an increase in precision oncology testing revenues, resulting from significant increases in average selling price, or ASP, per test, as well as higher development services revenues. The decline from the first quarter of 2020 was driven by lower test volumes caused by the COVID-19 pandemic, mostly offset by higher development services revenues.
17:22 Total precision oncology testing revenue for the second quarter was $51 million, comprised of $39.6 million from clinical tests and $11.4 million from biopharmaceutical tests. Precision oncology revenue from clinical tests included $2.6 million in revenue received from Medicare for Samples process in 2019. Given the age of the samples associated with this revenue, We do not believe it to be indicative of ordinary course of operations. Second quarter clinical precision oncology volume totaled 13,694 tests, up 15% from 11,875 tests in the prior year quarter, but down 10% from 15,257 tests in the first quarter of 2020 due to the COVID-19 pandemic.
18:19 Clinical Precision Oncology ASP was $2,893 in the second quarter of 2020, up 57% from $1,839 in the prior year period, and up 16% from $2,489 in the first quarter of 2020. The 57% increase in clinical ASP over the prior year quarter was due principally to the reimbursement from Medicare for testing of non-lung cancer samples in addition to lung samples starting in March 2020, plus a modest increase in reimbursement from commercial insurers and $2.6 million received from Medicare for samples processed in 2019.
19:04 In Q2, the processing of samples reimbursed by Medicare stabilized under the new coverage policy, and as a result, we recorded revenue on approximately 85% of Medicare samples in Q2, up from approximately 75% of Medicare samples in Q1. This increase in Medicare reimbursement plus a modest increase in reimbursement from commercial insurers as well as revenue from Medicare for samples processed from 2019 resulted in a 16% increase in clinical ASP in Q2 over Q1. Precision oncology revenue from biopharmaceutical tests in the second quarter totaled $11.4 million, down 44% from $20.2 million for the second year quarter and down 49% from $22.3 million in the first quarter of 2020.
19:55 Second quarter, Pharma Precision Oncology volume totaled 2,805 tests, down 47% from 5,285 tests in the prior year quarter. As expected, second quarter volume was lower than the prior quarter, down 47%, due mainly to the impact of the COVID-19 pandemic on customer programs. ASP was $4,054, up 6% from $3,827 in the prior year period, but down 4% from $4,230 in the first quarter of 2020. The ASP was driven by changes in the proportion of total biopharmaceutical tests using the Garden Omni test, which has a higher selling price than the Garden 360 test.
20:59 Developed services revenue in the second quarter totaled $15.3 million, up 29% from the prior year quarter and up 111% from the first quarter of 2020. The increase was primarily due to companion diagnostic revenue, including programs with Amgen and Janssen, which boosted development services revenue in the first half of 2020. Gross profit for the second quarter of 2020 was $43.9 million, compared to a gross profit of $37.1 million in the same period of the prior year and $47 million in the first quarter of 2020. Gross margin in the second quarter was 66% as compared to 69% during the second quarter of 2019 and 70% in the first quarter of 2020.
21:56 The decline in gross margin compared to the second quarter of 2019 was primarily due to a lower gross margin on development services revenue, the result of normal variability across programs. The decline in gross margin compared to the first quarter of 2020 was due principally to the lower ASP for pharma testing plus an increase in overhead cost per unit due to the decline in total volume of samples tested. Total operating expenses for the second quarter of 2020 were $98.5 million, an 88% increase from $52.4 million in the second quarter of 2019 and up 20% from $81.9 million in the first quarter of 2020.
22:48 R&D expenses for the second quarter of 2020 were $36.3 million compared to $19.5 million in the second quarter of 2019. The increase was primarily attributable to increased expense for our lunar programs, including the Eclipse clinical trial, our FDA submission for Garden 360, and other research and development programs, including development of our COVID-19 tests. Sales and marketing expenses for the second quarter of 2020 were $25.0 million, compared to $19.4 million in the second quarter of 2019.
23:33 The increase was due to growth in sales and marketing staff, plus spend on programs to increase education and awareness about liquid biopsy. General and administrative expenses for the second quarter were $37.2 million compared to $13.4 million in the second quarter of 2019. G&A expenses for the second quarter included $18.3 million in stock-based compensation, or SBC, related to market-based restricted stock units granted to the company's founders on May 26, 2020. The remaining increase in GM expense was $5.5 million, which was primarily due to additional staff to support the growth of the company, legal expenses, and the cost of compliance with the requirements of becoming a large accelerated public traveler with the SEC.
24:31 The market-based restricted stock units were designed to focus the founders on the long-term operational and strategic development of the company. including the successful development and commercialization of the key lunar programs. The design of the market-based restricted stock units builds upon the successful company performance that the founders have led to date and the board believes the market-based restricted stock units further align founders' interests with those of the company's long-term stockholders because the vesting will depend on creation of significantly enhanced We ended the second quarter of 2020 with $1.1 billion in cash, cash equivalents and Marketable Securities.
25:41 Beginning this quarter, we added disclosure of adjusted EBITDA, a non-GAAP financial measure to our financial reporting to assist management and investors in evaluating the performance of our core business by removing the impact of income or expenses attributable to material non-cash items, specifically stock-based compensation and Fair Value Remeasures due to the subjectivity, management judgment and market fluctuations involved in these amounts. We exclude certain other items because we believe that these incomes or expenses do not reflect expected future operating expenses. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance.
26:37 You will find a detailed presentation of non-GAAP adjusted EBITDA and a full reconciliation to GAAP net loss attributable to Garden Health, Inc. common stockholders in our Q2 2020 results press release and quarterly 10Q filed with the SEC. Our use of adjusted EBITDA as a non-GAAP financial measure is not intended to be considered in isolation from, as substitute for, or as superior to the corresponding financial measures prepared in accordance with GAAP. Non-GAAP adjusted EBITDA was a loss of $25 million in the second quarter of 2020, compared to $9 million in the second quarter of 2019.
27:25 The impact of COVID-19 created headwinds for the oncology space during the second quarter, and due to its unpredictable evolution, we do not believe that we can reasonably estimate the magnitude or duration of specific impacts on our business. Accordingly, we are not reinstating financial guidance at this time. As Helmy mentioned, we exited the second quarter with clinical test volumes similar to the levels we saw prior to the impacts from COVID-19. That said, we believe the effects from COVID are likely to continue to impact the oncology space in the near term. And we anticipate third quarter clinical volumes will be up modestly from the first quarter.
28:14 Clinical precision oncology ASP in the second quarter was $2,702 when we exclude the $2.6 million of revenue received from Medicare for samples processed in 2019. We expect this clinical ASP to remain steady through the balance of 2020. As AmirAli mentioned, we expect that the effects of COVID-19 may continue to impact biopharma sample testing volumes through the second half of the year. Nonetheless, our customers continue to demonstrate strong interest in our capabilities, and we saw record development services revenue in the second quarter. That said, given the lumpiness of our CDX programs, we do not expect development services to remain at this record peak for the second half of 2020.
29:06 At this point, I would like to turn the call back to Helmy for closing comments.
29:11 Thank you, Derek. Before closing, I want to again thank our team at Gardens for the strength, dedication, and effort they have shown, particularly over the past few months. In these unprecedented times, I have even more confidence in the value that liquid biopsy can bring to the cancer treatment paradigm. We are well prepared operationally, financially, and strategically to navigate through this challenging period, and we remain focused on our long-term opportunity ahead of us to transform cancer patient care. With that, we will now open it up to questions. Yes, sir. And ladies and gentlemen, just as a reminder in order to ask a question, Please press star and the number one on your telephone keypad.
29:57 Our first question comes from a line of Mr. Doug from Cowen.
30:03 Hey, guys. Good afternoon, and thank you for taking my questions. Starting on clinical testing revenues, that was up sequentially, as you know, quarter to quarter. I think a lot of folks, including me, were expecting a decline. Thank you very much. I'm just wondering if you've started to be able to be more successful in adding new accounts over the course of the quarter as the world started to open up a little bit more. I ask because in some ways it would be great to hear that you are able to once again open more accounts, but in other ways, if you're still challenged with that metric, it could be argued that the rebound in store sales is all the more impressive.
31:09 That's a great question, Doug, as you tell me. It's Yeah, it's really interesting when you look at the data. Clearly, we've been in the market now for five or six years. Over 7,000 oncologists out of the 10 or 12,000 have ordered our tests at least once. And so the majority of the market does have exposure to garden. They have used it at least once. And that's where we believe we have an advantage in this time. We think This sort of time period of uncertainty and lack of access, at least face-to-face, really favors the incumbents in this space, of which we are that in the liquid biopsy testing arena. And so we have seen and continue to see addition of new oncologists, but the majority of our business is really and many more.
32:41 Fundamental progress in terms of the KPIs we look at underlying those numbers. And so we do see some certainly positive signs of recovery. That said, we are seeing certain regions that are closing down again. There are clearly many hotspots that are raging on. And that has impact as well. There's some fatigue going on in terms of virtual consultations and so on in terms of these position offices. And so it's something we're continuing to monitor and we see the ebbs and flows regionally. But, you know, I think the underlying message is that, you know, we think we're building differential strength, I would say, in terms of the landscape as a whole, in terms of really the compatibility of our offering and the advantages of our offerings amidst the backdrop of COVID and the challenges that it presents.
33:45 Okay. Super helpful, Helmy. Thank you for that. Amir really walked through some of what you released during the quarter on Lunar 2, some nice data updates. I'm just wondering when we should expect the next data release and kind of building off of that, It's encouraging and, frankly, maybe even a little bit surprising to hear that Eclipse is getting going in terms of enrollment and site openings so quickly. That's good news for you, and, frankly, in terms of what it implies about what's going on with colonoscopies, I think that's a good sign for all of us. That being said, I'm just wondering, given the momentum you have there, are the original timelines in terms of when you'd expect completion and readouts, are still intact, or at this point, should we be thinking that there's going to be at least one to two months, maybe three months delay, given where you are right now?
34:43 Regarding data presentation, you can't expect in all major conferences in oncology or related GI congresses, we would have some kind of presence in terms of updates. Regarding Eclipse, actually, we are very pleased with our progress. In fact, during the days that patient enrollment was slowed down because of COVID, we put a lot of energy behind bringing new sites on. And I'm very happy that we have over 130 sites. By end of this quarter, we are going to basically reach our 150-site target that we had for Eclipse. Month of June was our record month.
35:32 in Q2 and all the quarters before M2 was even better in terms of enrolling patients in the trial. And we do believe that we can finish this study within the original timeframe that we mentioned last November, which was within the 24 months from FBI. And we think still we can finish this study even during these environments within the timeframe we mentioned earlier.
35:58 Okay. Super helpful. Last one, and then I'll leave it to others. Really pivoting to a completely different topic. I mean, I think a lot of us, or at least I tend to think of Garden as being primarily focused on internal development of products and advancement of internally developed products. That said, the balance sheet's in a really good spot. More broadly, there's clearly been a pickup in the pace of industry consolidation. I'm just wondering if there's any change in how you would describe your appetite and your readiness for more material M&A.
36:40 That's a great question.
36:42 I think certainly all of that is on the table in terms of having a balance sheet that we have right now. Obviously, I've done some small
36:54 I think if we think about the commercial channel that we've built, the part of the portfolio we have, where we're going in terms of the market, there's certainly a place for inorganically adding to that and increasing leverage in terms of the core competencies we have in our business. It's something that we're certainly open to and we We continue to look at opportunities.
37:25 Okay. Thanks again. And our next question comes from from SVB .
37:40 Great. Thanks, Helmy. So, first one on biopharma revenue. and thanks for the details there. I really appreciate those details. So, I think the important question there is, you know, despite the impact you're seeing due to COVID and prospective samples and the biobank retrospective samples, what would be helpful is if you can help us understand your view on the underlying studies that are driving those samples to you. Do you think those studies are simply delayed or is there any fundamental change in those studies, if you could clarify that? and provide us, if you can, in terms of when do you expect, you know, sort of those samples to return back to you and into the second half or, you know, maybe even later.
38:28 Thank you.
38:31 So what we experienced is actually a lineup, you know, what has already been known in terms of prospective studies sponsored by pharma companies on our prospective trial site. and what also we experienced is some of the major pharma companies are putting a lot of attention into COVID-19 vaccine development and they're keeping a fresh look into their pipeline activities. So having said that, we are very pleased with all the conversation we have across many We still expect that what we expect with COVID-19 is going to recall through the rest of the year, at least for a couple of quarters.
39:25 But we are optimistic about the future and all the conversations that we had around our portfolio products, especially on... Yeah, I mean, I'm going to add one thing, you know, this is on here.
39:38 You know, I think we're seeing, I think, very good underlying signs in terms of the business. You know, pipeline is progressing very strongly. as well as, you know, diversification in terms of the types of partners that are using Omni and, you know, kind of deepening use of that test. So, yeah, all the kind of underlying metrics we look at are looking good in our view.
40:01 Okay. That's great. And if I could have a follow-up on in terms of your Lunar One program, can you elaborate where you stand on different efforts? I know you're in a number of Biopharma collaborations and partnerships are ongoing. The COBRA trial that you have invested into and a few other studies. Maybe just give us a sense of where that stands and then potentially when can we see that product in recurrence monitoring markets this year or the next, if you could provide any color on that. Then I have a small follow-up.
40:39 Yeah, as you mentioned, actually, our Lunar 1 slash our MRD product, you know, initially we had the REO version of it, then we had the clinically validated version of that product for CRC, which we were running a few trials based on that. And I'm pleased, actually, we just saw the progress that we made. Even on the R&D side, we've been working for a while to expand. really multi-cancer types. So please would tell the progress that the team has made on that front and please state about some data sharing around that platform, which is around multi-cancer MRD device.
41:31 Okay, great. And last one, if I could, on COVID testing, I recall you were working on a differentiated high throughput platform and thanks for the update on that in terms of filing the EUA, anything you can provide in terms of the volumes per day that system can produce or cost or turnaround time and maybe potential pricing if you can. Thank you. Thanks for taking the questions.
41:56 Yeah, so, you know, this COVID test, and we thought about EUA a few weeks back, so, and in parallel, we are talking with lots of potential partners in terms of bringing that test up for EUA. The platform technology is pretty high throughput. We are bringing high throughput operation. Having said that, we never looked at COVID-19 as a new business line for us. We brought it up as a social responsibility. Even the partners that we are looking at are The ones that are in alignment with our mission and some of the value that we want to have in the field. On the other side, we are trying to make sure that, you know, this wouldn't be an activity at guard and that we would come at a loss.
42:57 But, you know, again, we are prioritizing the social responsibility here versus really making it a new business line item in our P&L.
43:08 Okay, great. Thanks, guys. Our next question comes from a Michael Peterson from J.P. Morgan.
43:20 Hey, thanks. Helmy, on the reimbursement front, you brought up, you know, for CMS, you know, a number of CMS payments for non-lung. Can you just give us a sense of what percentage of the payments today from CMS are non-lung? And I guess how you think about that, you know, trending until you have the FDA approval?
43:39 So, thank you. Approximately 85% of our Medicare samples are covered now under our current reimbursement from the RIDIAN. And whether it's lung or non-lung, it's about the same. So I think really the way you want to think of it is, you know, most all of our Medicare samples are covered now. There is an opportunity with an FDA approval on the NCV to have a slight increase in that. But at 85%, there's not. and, you know, a huge amount left to improve there.
44:16 Okay. And then, Derek, on the development services side, you noted, you know, the milestone component for CDX. Can you just talk about how significant the milestone piece was in the quarter?
44:27 It's actually making progress towards those milestones. So we don't take revenue on an individual milestone. It's a little bit of a misnomer in the way the wording was. We just continue to make progress. What we had was a lot of programs active in the quarter, so therefore we had a lot of progress in the quarter. Those programs, as you can well imagine with biopharma programs, there are peaks and valleys in those programs. So this happened to have been a very strong quarter for the companion diagnostic revenue, which is the bulk of the development services revenue.
45:12 Thanks. And then just one last one following up on the question earlier on Lunar One. You know, we've been hearing more about, you know, some off-label use. I guess as we kind of think about, you know, the commercialization strategy here, you've got the research you sell on the product and then the clinically validated, as you mentioned. Can you just talk on, you know, how material you think Lunar One could be for you guys going forward and to what extent, you know, you're making investments in the channel there to roll it out more broadly? Okay.
45:39 So in terms of actually the level of investments, we are very excited about it, and we have teams focused on that program. And, you know, our belief is, you know, one of the main things that needs to be done in the MRD space is proving the clinical utility in order to really accelerate the clinical adoption when you put it in a marketplace. We've been in conversation with all major KOLs who have a lot of experience with us on the Garden360 site around MRD. We have ongoing conversations around ISDs. But instead of just putting the clinical-grade tests that we have right now in the market, we always went with this philosophy that go aggressive.
46:40 on the clinical utilities are a question. When you think about this in long term, we do believe, actually, the way we are doing MRD assay is gonna revolutionize the patient journey in the oncology space, and it would really bridge the stories that we have on advanced cancer treatment selection, so adjuvant, neoadjuvant, and, you know, MRD-positive patient treatment selection, too, are the cancer detection pipeline that we have. So we are very excited about it and we're making a lot of investment around that space. Great, thank you. And our next question comes from Ms. Ivy May from Bank of America.
47:34 Hey, this is Ivy Ong for Derek today. Thank you for taking the question. Firstly, on Luna 2, I'm just wondering if you had any initial conversations with the CMS, since there are a lot of companies working on pan-cancer early detection disease. So I wanted to see if there's any feedback on pan-cancer reimbursement or multi-cancer reimbursement, or how are you thinking about reimbursement for multi-cancer in general? Thank you.
48:13 In our Lunar 2 CRC screening program that we have, we've been obviously in touch with agency, FDA, and national CMS, both sides. And I think we have a good picture of what it takes for FDA approval and national reimbursement on the Medicare side. And one of the reasons that I actually regard in strategy is to go after CRC screening first and maybe think of One of the reasons is reimbursement. Besides the clinical value unmaintained and technological advantages that CRC has, we believe the reimbursement pathway for CRC only screening is in fact very different than multi-cancer and there is a good pathway for it and a clean path for potential On the multi-cancer side, there are a lot of conversation on workshops that I'm pretty sure you guys are familiar with.
49:25 It's not easy, so we have to see what's going to happen on the multi-cancer side. But we are foolish about our strategy of going from our typical CRC device.
49:38 Great, thanks.
49:39 And then on biopharma,
49:42 We're seeing a lot of companies entering the liquid proxy space. So I wanted to see if you're seeing more competition for Omni and how does that shape the revenue trajectory going forward? And then if there's any quantifying color you could offer on how to look at the component diagnostic line going forward, it would be super helpful. Thank you.
50:07 I got a job done with Omni here. I would say that from a competition point of view, Lipid Biopsy Space has always had dozens of companies in it from even eight years ago when we started. Many of those companies still exist and some of them are gone and there are new companies that have come in. I would say from a competitive point of view, Omni is really second to none. It's head and shoulders above and really any other offering we see in this space. And so that's not something we frankly see a lot of in terms of, you know, competitive noise, especially with respect to Omni. You know, I think we're much more, I would say, you know, focused and later focused on the evolution of the therapeutic pipeline and where that's going and continuing to meet and really the requirements in terms of the types of biomarkers that are of interest to our biopharma partners.
51:13 So that's really what we're focused on in terms of really listening to our customers and moving and advancing our offerings in step with that.
51:27 Great, thank you. And lastly, if I may, on G360, could you update us on the FDA COVID situation and how that conversation has been going?
51:36 I know there are some delays due to the whole COVID situation, but I wanted to see if there's any updates.
51:41 I appreciate the call.
51:45 Yeah, actually, the experience that we have, you know, I don't believe we experienced any slowdown in our FDA interaction because of COVID. We are very pleased with the progress that we made and based on all the conversation, I think we are very close. So we stay tuned.
52:07 Great. Thank you again. And our next question comes from a Patrick Donnelly.
52:19 Thanks for taking the question. Yeah, thanks for taking the question, guys. Helmy, maybe just on the second wave of COVID, you mentioned you saw a little bit of pullback on the volume side. Can you just talk through, I know you guys get some pretty real-time data geographically, how sharp are you seeing the pullbacks? It doesn't seem overly concerned, given by the guidance you guys gave, but just curious in terms of your perspective on how impactful the second wave has been and how confident you are in the outlook of this uptick from here.
52:49 Yeah, that's a great question. I mean, certainly, Nowhere as close to, I think, the first wave and the impact that was there. I think the challenge of the first time was it was the first time by definition a lot of these offices have been dealing with this kind of situation. And so there was just a lot of learning in terms of how to deal with this sort of new normal. We see certainly a lot more resiliency in terms of impact of these second waves and reclosures and so on. You know, and so I would say these are... I would say minor perturbations regionally as you see some of these closures and some of the orders that are going into place regionally. So it does have impact and that's why I think it's difficult to forecast.
53:37 Obviously if you have a lot of these happening simultaneously and through multiple parts of the country then it's certainly going to have some negative impact on We've been seeing these kind of ripple through different parts of the nation and kind of come back. And so it's certainly less severe so far than what we saw in March.
54:08 That's good to hear. Yeah, and then maybe just one on mobile phlebotomy. You know, I know you talked about that being a good opportunity in 2Q and even beyond as maybe the market focus shifts a little bit towards that. How did that trend relative to expectations and just your go-forward view on that side as well?
54:26 Yeah, I think as we mentioned last call, we certainly saw certain regions that leveraged that offering quite a bit. That said, you know, it's just the very nature of liquid biopsy is So much simpler than a tissue biopsy-based approach. And if you think about the coordination of multiple medical specialties, whether it's pathology or a surgical oncologist or interventional radiologist, the fact that you essentially can empower oncologists with the ability to identify biomarkers through a simple blood test by itself and by its very nature is very well suited to the practical realities that COVID imparts on this base right now. And so even that alone without mobile phlebotomy is something that's a huge advantage and something very beneficial to physicians.
55:18 But clearly there's going to be a subset of patients that find it very difficult to come in, and that's where mobile phlebotomy has been really key in terms of being able to provide a complete offering for really the majority of patients that an oncologist may have. So it's been something that's very synergistic with Ease of use of liquid biopsy itself. Clearly our turnaround time is sometimes half or a third of other tissue-based approaches. And so you really just can't beat the holistic offering in our view compared to some of the other approaches of getting that information. That's helpful.
56:03 Thanks, Helmy. Thank you. And our next question comes from a Max from Canaccord.
56:16 Hi, this is Max Basici. So the supply of COVID-19 testing in the U.S. is still well below demand. The U.S. is conducting about 700,000 COVID tests per day by our estimates, which is a bit underwhelming compared to, say, China, which has capacity to process around 5 million tests per day. So what role or magnitude do you think you can play in COVID-19 testing now that testing is becoming more widely available for asymptomatic individuals versus the early prioritization of testing for healthcare workers and first responders?
56:59 Yeah, that's a great question. So we certainly are providing testing on a weekly basis for our employees at gardens and We found that to be, you know, from multiple aspects, very critical for continuity of the business, for ensuring, I think, the safety of our employees and really making sure that we can continue to weather the storm of, you know, these surges and the raging pandemic that's going on around us all. And so we see firsthand the value of Testing for surveillance and asymptomatic individuals. And so it's something that we continue to explore. We're speaking with multiple partners and so on in terms of, you know, the kind of potential, us potentially jumping in and really helping with the undersupply that exists today. But I would say, you know, stay tuned and we'll be happy to update
58:07 Great. And then on the Salesforce, can you just share how your Salesforce is adjusting to the COVID-19 virtual environment? You know, what sort of initiatives or targeting strategies are sales reps having success with?
58:24 Yeah, so I think it's a lot of what we outlined, I think, in our previous earnings call. It's really the fact that we're able to do a lot of Thank you very much. and a number of other programs that are specifically tailored to those affected by COVID.
59:11 And so we found that that overall offering was very helpful in terms of really supporting physician offices in their time of need and for some of these kind of challenging times. And we believe we were one of the earlier companies to provide that kind of suite of services to, you know, many of these offices in terms of achieving the kind of rebound that we saw during the quarter.
59:44 Great. Thanks for taking the question. And our next question comes from a Mr. David with Guggenheim Securities.
59:56 Hi. Thank you for taking the question. This is David Westenberg. So my first question is, with Keytruda's approval in PMB high-patients, Does that maybe change the look in terms of the ramp for Garden Omni? And if it doesn't, can you at least talk about the appetite for larger panels from oncologists?
1:00:19 So, currently, actually, the clinical product that we have We've been working with a bunch of pharma companies who were investing heavily on the TNV side, not just TNV, even on the other kind of biomarkers that we have in Garden Omni. And still, we see there's a lot of excitement. The pipeline conversation that we have around Garden Omni is pretty robust, although we are cautious. One of the drivers has been TMV.
1:01:15 Got it. Thank you. And then just a quick one for Derek. As we're modeling the back half of the year, is there anything to call out in terms of comp? I know that you've had pretty strong quarters, and then you've also had some maybe back payments from certain payers. I just want to make sure that our models are tight in the back half of the year as we move forward. Think about year-over-year comps, and I'll take the rest offline.
1:01:40 So what we tried to do is give you nuggets of information. We expect modest increase in clinical volume in Q3 compared to Q1. So not comparing to Q2, which is obviously a down quarter. Going all the way back to Q1, we're expecting modest volume increase in Q3. We also indicated that for ASP purposes, you want to pull out the effect of that revenue we earned from samples processed in 2019. There were some changes in the Medicare interpretations of the NPD, which allowed some prior samples to get billed and reimbursed.
1:02:25 So you shouldn't assume that. So I gave you a $2,700 ASP for you to use. And then, you know, we talked about the biopharma. It was a record quarter for development services. Probably won't have a record quarter every quarter.
1:02:47 Thank you. And that is all the questions we have at this time.
1:03:05 Thank you, everyone, and look forward to having you exported. And ladies and gentlemen, this does conclude today's conference call. Thank you very much for your participation. You may now disconnect.
Follow Guardant Health, Inc. into a list and get an email when it puts out news.
Head of Investor Relations
Chief Executive Officer & Co-Founder
President & Co-Founder
Vice President of Finance
Analyst, Cowen & Co.
Analyst, SVB Leerink
Analyst, J.P. Morgan
Analyst, Bank of America
Analyst
Analyst, Canaccord Genuity
Analyst, Guggenheim Securities